Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.

PURPOSE The association between common functional polymorphisms from the CYP17, CYP19, CYP1B1, and COMT genes involved in the estrogen metabolism and the risk of prostate carcinoma was evaluated. PATIENTS AND METHODS The study investigated 1,983 white French men (1,101 patients with prostate cancer and 882 healthy controls) aged between 40 and 98 years. The different alleles and genotypes were analyzed according to case-control status, aggressiveness pattern of the tumors, age at onset, and family history of cancers. RESULTS The VV (high activity) genotype of the V432L polymorphism from CYP1B1 (odds ratio [OR] = 1.36; 95% CI, 1.03 to 1.79; P = .031), and the long allele (> 175 bp) of the TTTA repeat from CYP19 (OR, 1.26; 95% CI, 1.08 to 1.47; P = .003) were significantly associated with the risk of prostate cancer. An additive effect was observed when we combined the two at-risk alleles (OR = 1.63; 95% CI, 1.24 to 2.13; P < .001). The association was stronger for the CYP1B1 VV genotype (OR = 1.55; 95% CI, 1.13 to 2.13; P = .007) among the group of patients with highly aggressive disease. Stratification by age at onset showed that the associations of CYP1B1 and CYP19 variants were largely confined to the younger prostate cancer patients. CONCLUSION This association between polymorphisms from genes related to estrogen metabolism and prostate cancer risk suggest new clinical considerations in the management of prostate cancer: the development of new prevention trials based on genetic profiling and the evaluation of specific inhibitors involving the estrogen pathways.

[1]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[2]  J. Witte,et al.  Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. , 2006, Carcinogenesis.

[3]  B. Leibovich,et al.  Obesity and survival after radical prostatectomy: A 10‐year prospective cohort study , 2006, Cancer.

[4]  R. Sobti,et al.  CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. , 2006, DNA and cell biology.

[5]  T. Habuchi,et al.  Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Hindley,et al.  EXPRESSION OF HORMONE-/CARCINOGEN-METABOLISING ENZYMES IN THE PROSTATE: CLUES INTO PERIPHERAL-ZONE SUSCEPTIBILITY? , 2006 .

[7]  A. Sparreboom,et al.  Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention , 2006, Molecular Cancer Research.

[8]  D. Pookot,et al.  Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[9]  J. Schleutker,et al.  Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. , 2006, Cancer research.

[10]  D. English,et al.  Circulating Steroid Hormones and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[11]  L. Leung,et al.  Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. , 2005, International journal of oncology.

[12]  H. Honda,et al.  The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. , 2005, European urology.

[13]  M. Dowsett,et al.  Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men. , 2005, The Journal of nutrition.

[14]  J. Witte,et al.  Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11α in Prostate Cancer Risk and Aggressiveness , 2005, Cancer Epidemiology Biomarkers & Prevention.

[15]  Albert M. Levin,et al.  Identifying Susceptibility Genes for Prostate Cancer—A Family-Based Association Study of Polymorphisms in CYP17, CYP19, CYP11A1, and LH-β , 2005, Cancer Epidemiology Biomarkers & Prevention.

[16]  M. Terris,et al.  Body mass index as a predictor of prostate cancer: development versus detection on biopsy. , 2005, Urology.

[17]  C. Maier,et al.  Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. , 2005, Anticancer research.

[18]  M. Forrest,et al.  Association between hormonal genetic polymorphisms and early-onset prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.

[19]  J. Witte,et al.  No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  N. Fullwood,et al.  CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. , 2004, Cancer letters.

[21]  J. Little,et al.  CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review. , 2004, American journal of epidemiology.

[22]  O. Cussenot,et al.  Prevention of prostate cancer by androgens: experimental paradox or clinical reality. , 2004, European urology.

[23]  T. Araki,et al.  Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. , 2004, Anticancer research.

[24]  M. Brandi,et al.  A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  S. Ho.  Estrogens and anti‐estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates , 2004, Journal of cellular biochemistry.

[26]  Timothy F. Donahue,et al.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Cavalieri,et al.  Estrogen metabolites, conjugates, and DNA adducts: possible biomarkers for risk of breast, prostate, and other human cancers. , 2004, Advances in clinical chemistry.

[28]  H. Yamanaka,et al.  Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. , 2003, Anticancer research.

[29]  Kazuto Ito,et al.  Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol‐O‐methyltransferase are associated with familial prostate carcinoma risk in a Japanese population , 2003, Cancer.

[30]  J. Ioannidis,et al.  Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  E. Cavalieri,et al.  A Unified Mechanism in the Initiation of Cancer , 2002, Annals of the New York Academy of Sciences.

[32]  J. Cauley,et al.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  O. Cussenot,et al.  Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways , 2001, Cancer.

[34]  B. Green,et al.  Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. , 2000, Pharmacogenetics.

[35]  M. Bosland.  The role of steroid hormones in prostate carcinogenesis. , 2000, Journal of the National Cancer Institute. Monographs.

[36]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  D. Bell,et al.  An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. , 1997, Cancer research.

[38]  G. Coetzee,et al.  Genetic susceptibility to cancer from exogenous and endogenous exposures , 1996, Journal of cellular biochemistry. Supplement.